Physicians' Academy for Cardiovascular Education

Unhiding hypertrophic cardiomyopathy, a call for action

Listen to the podcast
10' education - Sep. 28, 2022 - Antonis Pantazis, MD - London, UK

Video navigation menu

  • What is hypertrophic cardiomyopathy (HCM)? 00:17
  • Genetic etiology and pathogenesis of HCM 02:56
  • Risk of complications, symptoms and family screening  08:06
  • Action points  12:49


Show transcript

Educational information

This lecture by Antonis Pantazis was part of the EBAC-accredited symposium "Innovative therapeutic approaches in hypertrophic cardiomyopathy" held during the ESC congress 2022.


Antonis Pantazis is a Consultant Cardiologist and Clinical Lead for the Cardiomyopathy and the Inherited Cardiovascular Conditions Service at the Royal Brompton and Harefield Hospitals in London. Dr Pantazis is the Chairman of the nucleus of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. In his clinical practice, he has a special interest in the genetic diagnosis, deep phenotyping and patient-centred management of cardiomyopathies. He is leading a programme for the management of Left Ventricular Outflow Tract Obstruction in Hypertrophic Cardiomyopathy.


This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.


Funding for this educational program was provided by an unrestricted educational grant from Bristol Myers Squibb.

View the slides of this presentation

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: